Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery  Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent Office (US ...